In the midst of the pandemic, health care providers have faced an uphill battle in communicating and disseminating information about choriorectitis, a disease that can cause serious complications for patients.
“The CDC has been trying to make choriometinitis as easy to communicate as possible and to get people vaccinated,” said Dr. Thomas M. Koehn, a professor of epidemiology at Harvard Medical School who specializes in infectious disease.
But the CDC is currently relying on the personal health record of people who are suspected of having the disease to disseminate the information, which means that patients who don’t want to talk about their symptoms may be less likely to seek medical care.
“People who are afraid of sharing their symptoms might be less willing to seek help,” Koehr said.
The CDC’s effort to disseminates the most accurate information about the disease and how to manage it is a new strategy, he said.
But even though the CDC has a plan in place, Koehl said, the agency faces challenges when it comes to disseminating the information.
“It’s really important that we’re reaching the widest audience possible to try to get the message out,” he said, “but the challenge is that we are not able to disseminated information across all parts of the country, and that is where our challenge lies.”
This is the second pandemic that has prompted the CDC to look into how to better disseminate information about CMV.
In 2015, the CDC published a guide for patients who are at risk for developing CMV to get more information and resources about the virus, including information about screening.
The guide included a link to the CDC’s website and was designed to give people who were at high risk for CMV the chance to learn more about the illness and how it can affect their health.
“I think it was a really important step forward because it gave people who have been at high-risk information about how to be more prepared for it,” said Stephanie T. M. Brown, a medical doctor and clinical assistant professor of infectious diseases at Northwestern University who specializes at the intersection of disease prevention and public health.
She said the guide should have been a standard in health care systems across the country.
“There’s an enormous amount of pressure on health care organizations to be able to offer information that is timely and relevant,” she said.
“They’re not going to get all the information that they need if they don’t have a platform to do that.”
Dr. Daniel M. Reiss, an infectious diseases physician and director of the Institute for Health Policy Research at the University of California, San Francisco, said the information the CDC provided to the public should be the primary source for CMVD information.
He said that the information was not a comprehensive overview of CMV, and there are many other diseases that people with CMV can develop.
“CMV is not going anywhere,” Reiss said.
In a recent editorial in The New England Journal of Medicine, Dr. William H. Frey, a member of the CDC advisory committee, noted that the CDC also should have created a website for CMVE and given people who might not be at high risks the opportunity to learn about it.
“To the extent that we have a way to inform people about this disease, we should have a website that is more accurate than what we have now,” he wrote.
Frey also said that there is a growing body of evidence showing that people who get CMV are more likely to develop other diseases, including cancers.
“Cancer is the leading cause of death in the United States,” he added.
The authors of the editorial also noted that there are no new vaccines or other therapies for CMVT that are being tested in clinical trials, which could lead to an increase in the number of people infected.
The most recent National Health and Nutrition Examination Survey, which includes questions about CMVT, was conducted by the Centers for Disease Control and Prevention in 2015 and 2016.
The survey included a question about the prevalence of CMVT among people aged 25 to 64, which was the survey’s highest number of cases since it began collecting data in 2006.
About 13.5 percent of respondents said they had been tested for CMVP, which is about half the rate that they had reported before the pandorectalgia pandemic began.
Researchers at the Centers also found that about 12 percent of those who were tested were diagnosed with CMVT and had not been diagnosed with other forms of the disease.
The study was funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health.
The National Institutes for Health supported the work.
Contact Stephanie Ruhle at [email protected]
Follow The Columbia Health Blog on Twitter: @columbiashealthblog.